Putera Prakoso Bhairawa, Widianingsih Ida, Ningrum Sinta, Suryanto Suryanto, Rianto Yan
Faculty of Social and Political Sciences, Universitas Padjadjaran, Jalan Bukit Dago Utara Nomor 25, Bandung 40135, Indonesia.
Research Center for Public Policy - National Research and Innovation Agency, Gedung SWS Lantai 6, Jln. Jend Gatot Subroto No. 10, Jakarta Selatan 12710, Indonesia.
Health Policy Technol. 2022 Sep;11(3):100650. doi: 10.1016/j.hlpt.2022.100650. Epub 2022 Jul 3.
R&D serves as one of the imperative aspects in handling the COVID-19 pandemic. Since the Indonesian government has declared the COVID-19 pandemic as a national disaster, a number of accelerated regulations were stipulated, engaging research and innovation acknowledged as Science, technology, and innovation (STI) Policy. The results of the regulation mapping in Indonesia during 2020-2021 include the 9 regulations (categorized as STI Policy and dominated by institutional settings of 44.4%, operational mechanisms of 33.3%, and legal devices of 22.3%) as an attempt to address the COVID-19 pandemic. Hence, it is expected that the implementation of STI Policy plays a role in generating the 50 innovation products through the COVID-19 research and innovation consortium.
The COVID-19 pandemic has been declared as a national disaster in Indonesia. There are nine regulations in the field of Science, technology, and innovation (STI) Policy set by the Indonesian government until July 2021, which regulate institutions, by institutionalizing the implementation of research and innovation in the health sector. The institution is acknowledged as the COVID-19 Research Consortium, consisting of government R&D institutions, universities, industrial R&D institutions, professional associations, regulators, industry, and 50 research and innovation products which have been launched by this consortium.
研发是应对新冠疫情的重要方面之一。自印度尼西亚政府宣布新冠疫情为国家灾难以来,已制定了多项加速法规,涉及被视为科学、技术和创新(STI)政策的研究与创新。2020 - 2021年印度尼西亚法规映射的结果包括9项法规(归类为STI政策,其中机构设置占44.4%、运行机制占33.3%、法律手段占22.3%),作为应对新冠疫情的一项举措。因此,预计STI政策的实施将通过新冠疫情研究与创新联盟在产生50种创新产品方面发挥作用。
新冠疫情在印度尼西亚已被宣布为国家灾难。截至2021年7月,印度尼西亚政府在科学、技术和创新(STI)政策领域制定了9项法规,通过将卫生部门的研究与创新实施制度化来规范机构。该机构被确认为新冠疫情研究联盟,由政府研发机构、大学、产业研发机构、专业协会、监管机构、行业组成,并且该联盟已推出了50种研究与创新产品。